[{"id":"b38f7192-0406-4c42-9815-ea388526bccb","acronym":"","url":"https://clinicaltrials.gov/study/NCT01973309","created_at":"2021-01-17T17:42:44.579Z","updated_at":"2024-07-02T16:36:41.269Z","phase":"Phase 1b","brief_title":"A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer","source_id_and_acronym":"NCT01973309","lead_sponsor":"OncoMed Pharmaceuticals, Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • vantictumab (OMP-18R5)"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 09/01/2013","start_date":" 09/01/2013","primary_txt":" Primary completion: 06/01/2017","primary_completion_date":" 06/01/2017","study_txt":" Completion: 12/01/2017","study_completion_date":" 12/01/2017","last_update_posted":"2020-09-09"}]